Innomech has designed and developed a pilot scale production system for Aston Particle Technologies to help the company accelerate the commercialisation of its innovative dry particle coating technology for use within the pharmaceutical industry
Innomech’s pilot scale production system features a touchscreen recipe-based control system
Aston Particle Technologies (APT) is developing a one-step particle engineering technology to enable challenging active pharmaceutical ingredients to be dry powder coated onto carrier particles: without needing heat, solvents or pressure.
Target applications for this processing technology breakthrough include the development of new dry powder inhaler formulations, improving the solubility of poorly water-soluble drugs and developing taste-masking solutions for bitter-tasting drugs.
Innomech has designed the new easy-to-use system to process up to two kilograms of pharmaceutical powders which is a 100-fold increase on the capacity of APT’s existing lab-scale, proof of principle equipment.
The system provides a fluidised environment for particle contact and adsorption of cohesive material over coarse particles without the need for solvent and heat.
Pressure and temperature sensors and an ultra-efficient heat exchanger are used to monitor and maintain the required process conditions.
A touchscreen integrated with a recipe-based control system allows operators to quickly and easily call up and store the required process conditions for specific production batches.
The system has been designed for easy cleaning and maintenance by minimising the surfaces and gas flow paths that come into contact with pharmaceutical powders. It uses a HEPA filtration system to ensure operator safety.
Professor Afzal Mohammed, CTO and founder of Aston Particle Technologies, said: “Innomech is the perfect system development partner for Aston Particle Technologies because of its extensive knowledge and experience in developing equipment for use in pharmaceutical and medical device manufacturing environments.
“The company’s new pilot-scale system will allow us to demonstrate the scalability of our technology and to carry out further process development studies for a range of pharmaceutical applications.”